Asia Pacific CAR T cell Therapy Market

Asia Pacific CAR T Cell Therapy Market Size (2024 to 2032)

The size of the Asia Pacific CAR T Cell Therapy Market was worth USD 0.54 billion in 2023. The Asia Pacific market is anticipated to grow at a CAGR of 14.32% from 2024 to 2032 and be worth USD 1.80 billion by 2032 from USD 0.62 billion in 2024.

MARKET SCENARIO

Increased funds from government organizations and adoption of advanced technologies in hospitals and clinics are undoubtedly significant factors for the market to grow in the Asia Pacific. It is proven that CAR T cell therapy is very much efficient in treating cancer, and this is elevating the growth rate of the market enormously. Growing older people is another factor propelling the demand for CAR T cell therapy in the Asia Pacific. An increasing number of people suffering from chronic diseases is accelerating the size of the market. In the Asia Pacific, more than 2000 clinical trials have been conducted using this technique, solely enhancing market demand. 

However, this treatment procedure's cost is very high, which ordinary people cannot afford, and is slowly impeding the growth rate of the CAR T cell therapy market in the Asia Pacific. Stringent rules and regulations by the government in approving new techniques limit the market demand. Besides, the shortage of skilled professionals in the laboratories to perform clinical trials is hampering the market's demand. Inadequate reimbursement policies in underdeveloped countries are likely to impact the market's growth rate negatively. 

SEGMENTAL ANALYSIS

Asia Pacific CAR T Cell Therapy Market Analysis By Target Antigen

• CD20
• EGFRV III
• CD19
• HER2
• MESO
• CD22
• BCMA
• GD2
• CD30
• HER1
• CD33

Asia Pacific CAR T Cell Therapy Market Analysis By Application

• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse large B-cell lymphoma
• Acute Lymphoblastic Leukemia

Asia Pacific CAR T Cell Therapy Market Analysis By Product

• Allogeneic
• Autologous

Asia Pacific CAR T Cell Therapy Market Analysis By Therapies

• Axicabtagene ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

Asia Pacific CAR T Cell Therapy Market Analysis By End-User

• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

GEOGRAPHICAL ANALYSIS

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Asia Pacific is estimated to reach the highest CAGR in the coming years. Growing knowledge of the availability of different treatment procedures through digital advertisements bolsters the CAR T cell therapy market's growth. 

China is leading with the highest market shares owing to the increasing number of hospitals with excellent infrastructure. The launch of innovative techniques with advanced technologies is surging the demand of the market. According to a recent survey, around 4.3 million people have cancer in China. 

India is next to China in dominating the shares of the CAR T cell therapy market. The number of cancer cases in India is projected to surge in the coming years due to lifestyle changes. Increasing pharmaceutical companies and a rise in the number of clinical trials are fuelling the market's growth rate. Introducing these techniques to treat cancer elevates this market's demand for this country's extent.

Japan is expected to have significant growth opportunities in the coming years, given the growing economy over the past few years. Also, focusing on improving the quality of healthcare services by introducing various techniques is boosting market demand.  

KEY MARKET PLAYERS

Notable companies in the APAC CAR T Cell Therapy Market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.